1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Germ Cell Tumors - Pipeline Review, H1 2015

Germ Cell Tumors - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 47 pages

Germ Cell Tumors - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Germ Cell Tumors - Pipeline Review, H1 2015’, provides an overview of the Germ Cell Tumors’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Germ Cell Tumors, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Germ Cell Tumors and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Germ Cell Tumors
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Germ Cell Tumors and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Germ Cell Tumors products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Germ Cell Tumors pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Germ Cell Tumors
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Germ Cell Tumors pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Germ Cell Tumors - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Germ Cell Tumors Overview 6
Therapeutics Development 7
Pipeline Products for Germ Cell Tumors - Overview 7
Pipeline Products for Germ Cell Tumors - Comparative Analysis 8
Germ Cell Tumors - Therapeutics under Development by Companies 9
Germ Cell Tumors - Therapeutics under Investigation by Universities/Institutes 10
Germ Cell Tumors - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Germ Cell Tumors - Products under Development by Companies 13
Germ Cell Tumors - Products under Investigation by Universities/Institutes 14
Germ Cell Tumors - Companies Involved in Therapeutics Development 15
ArQule, Inc. 15
Novartis AG 16
Philogen S.p.A. 17
Tolero Pharmaceuticals, Inc. 18
Germ Cell Tumors - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
alvocidib hydrochloride - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Cell Therapy 1 for Oncology - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
ribociclib - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Small Molecules to Inhibit Tubulin for Oncology - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Tetravil - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
tivantinib - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Germ Cell Tumors - Recent Pipeline Updates 39
Germ Cell Tumors - Dormant Projects 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47

List of Tables

Number of Products under Development for Germ Cell Tumors, H1 2015 7
Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Germ Cell Tumors - Pipeline by ArQule, Inc., H1 2015 15
Germ Cell Tumors - Pipeline by Novartis AG, H1 2015 16
Germ Cell Tumors - Pipeline by Philogen S.p.A., H1 2015 17
Germ Cell Tumors - Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 23
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Germ Cell Tumors Therapeutics - Recent Pipeline Updates, H1 2015 39
Germ Cell Tumors - Dormant Projects, H1 2015 45

List of Figures

Number of Products under Development for Germ Cell Tumors, H1 2015 7
Number of Products under Development for Germ Cell Tumors - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Top 10 Targets, H1 2015 20
Number of Products by Stage and Top 10 Targets, H1 2015 21
Number of Products by Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Top 10 Routes of Administration, H1 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25
Number of Products by Top 10 Molecule Types, H1 2015 26
Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.